Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Current Opinion in Pulmonary Medicine
|
February 3, 2026
Rethinking pneumonia in terms of the lung microbiome
Nicolas Gordon, Leopoldo N Segal, Benjamin G Wu
Journal of Translational Medicine
|
July 23, 2015
Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer
Jung-Min Lee, Nicolas Gordon, Jane B Trepel, et al.
Oncotarget
|
May 14, 2019
Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk
Erika J Lampert, John L Hays, Elise C Kohn, et al.
Gut
|
January 9, 2025
Induction of macrophage efferocytosis in pancreatic cancer via PI3Kγ inhibition and radiotherapy promotes tumour control
Shannon Nicole Russell, Constantinos Demetriou, Giampiero Valenzano, et al.
Biorxiv : the Preprint Server for Biology
|
March 30, 2023
PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer
Nicolas Gordon, Peter T Gallagher, Neermala Poudel Neupane, et al.
Molecular Oncology
|
January 14, 2026
PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer
Nicolas Gordon, Peter T Gallagher, Orly I Richter, et al.
Journal of the National Cancer Institute
|
May 21, 2014
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses
Jung-Min Lee, John L Hays, Christina M Annunziata, et al.
Oncotarget
|
November 8, 2017
Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer
Jung-Min Lee, John L Hays, Victoria L Chiou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2016
Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer
Jung-Min Lee, Cody J Peer, Minshu Yu, et al.
Nature Communications
|
January 16, 2021
The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair
Ayesha A Shafi, Chris M McNair, Jennifer J McCann, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Current Opinion in Pulmonary Medicine
|
February 3, 2026
Rethinking pneumonia in terms of the lung microbiome
Nicolas Gordon, Leopoldo N Segal, Benjamin G Wu
Journal of Translational Medicine
|
July 23, 2015
Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer
Jung-Min Lee, Nicolas Gordon, Jane B Trepel, et al.
Oncotarget
|
May 14, 2019
Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk
Erika J Lampert, John L Hays, Elise C Kohn, et al.
Gut
|
January 9, 2025
Induction of macrophage efferocytosis in pancreatic cancer via PI3Kγ inhibition and radiotherapy promotes tumour control
Shannon Nicole Russell, Constantinos Demetriou, Giampiero Valenzano, et al.
Biorxiv : the Preprint Server for Biology
|
March 30, 2023
PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer
Nicolas Gordon, Peter T Gallagher, Neermala Poudel Neupane, et al.
Molecular Oncology
|
January 14, 2026
PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer
Nicolas Gordon, Peter T Gallagher, Orly I Richter, et al.
Journal of the National Cancer Institute
|
May 21, 2014
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses
Jung-Min Lee, John L Hays, Christina M Annunziata, et al.
Oncotarget
|
November 8, 2017
Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer
Jung-Min Lee, John L Hays, Victoria L Chiou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2016
Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer
Jung-Min Lee, Cody J Peer, Minshu Yu, et al.
Nature Communications
|
January 16, 2021
The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair
Ayesha A Shafi, Chris M McNair, Jennifer J McCann, et al.
Page
of 2